| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/09/2009 | CA2710388A1 Treatment of abnormal or excessive scars |
| 07/09/2009 | CA2710379A1 Compositions containing sesamin-class compound(s) and quercetin glycoside(s) |
| 07/09/2009 | CA2710318A1 Drugs as well as their production and use in the treatment of pain-associated neuropathies |
| 07/09/2009 | CA2710271A1 Enhancing photostabilization of oxymetazoline |
| 07/09/2009 | CA2710240A1 C-21 thioethers as glucocorticoid receptor agonists |
| 07/09/2009 | CA2710194A1 Inhibitors of p13 kinase |
| 07/09/2009 | CA2710149A1 C20-c21 substituted glucocorticoid receptor agonists |
| 07/09/2009 | CA2710092A1 Pyridazinone derivatives |
| 07/09/2009 | CA2709993A1 Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same |
| 07/09/2009 | CA2709961A1 Benzothiazole and benzoxazole derivatives and methods of use |
| 07/09/2009 | CA2709875A1 Improved compositions and methods for the delivery of nucleic acids |
| 07/09/2009 | CA2709784A1 Method for altering the lifespan of eukaryotic organisms |
| 07/09/2009 | CA2709710A1 Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors |
| 07/09/2009 | CA2709709A1 Manufacture of tablet |
| 07/09/2009 | CA2709694A1 Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use |
| 07/09/2009 | CA2709524A1 Combination between an isothiocyanate and levodopa for parkinson's disease treatment |
| 07/09/2009 | CA2709227A1 Stable elsamitrucin salt formulations |
| 07/09/2009 | CA2709202A1 Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| 07/09/2009 | CA2708400A1 A slow-release formulation based on an association of glycogen and alginate |
| 07/09/2009 | CA2708399A1 Composition for the treatment of osteoarthritis |
| 07/09/2009 | CA2708394A1 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid .gamma.-lactone derivative, use thereof and medicinal products containing the derivative |
| 07/09/2009 | CA2707789A1 Phenyl acetic acid derivatives as inflammation modulators |
| 07/09/2009 | CA2707520A1 Herbicidal pyridazinone derivatives |
| 07/09/2009 | CA2707339A1 (aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor |
| 07/09/2009 | CA2706735A1 Tetrahydro-imidazo[1,5-.alpha.]pyrazine derivatives, preparation process and medicinal use thereof |
| 07/09/2009 | CA2706566A1 Chromane derivatives as trpv3 modulators |
| 07/09/2009 | CA2706114A1 Compositions and methods for treating diseases of the nail |
| 07/09/2009 | CA2704125A1 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents |
| 07/09/2009 | CA2702478A1 Ophthalmic composition |
| 07/08/2009 | EP2077326A1 Novel nucleic acid |
| 07/08/2009 | EP2077293A1 Block copolymer for drug complex and pharmaceutical composition |
| 07/08/2009 | EP2077271A1 Macrolide derivative |
| 07/08/2009 | EP2077268A1 Process for preparing inhibitors of nucleoside metabolism |
| 07/08/2009 | EP2077267A1 Fused heterocyclic compound |
| 07/08/2009 | EP2077266A1 2-pyridinecarboxamide derivative having gk-activating activity |
| 07/08/2009 | EP2077265A1 Salt of sulfinylbenzimidazole compound, and crystal and amorphous form thereof |
| 07/08/2009 | EP2077263A1 Quinazolines and related heterocyclic compounds and their therapeutic use |
| 07/08/2009 | EP2077262A1 Iminopyridine derivative and use thereof |
| 07/08/2009 | EP2077260A1 Amide compound or salt thereof, and biofilm formation inhibitor, biofilm remover and bactericide each using the amide compound or salt thereof |
| 07/08/2009 | EP2077126A1 Analgesic apatitic calcium-phosphate cement |
| 07/08/2009 | EP2077122A1 Therapeutic agents for irritable bowel syndrome |
| 07/08/2009 | EP2077120A2 Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient |
| 07/08/2009 | EP2077114A1 Pharmaceutical preparation for treating fibromyalgia |
| 07/08/2009 | EP2077113A1 Treatment of autoimmune diseases |
| 07/08/2009 | EP2077112A1 Methods and compositions using thalidomide for the treatment and management of cancers and idiopathic pulmonary fibrosis |
| 07/08/2009 | EP2077111A1 Antidepressant agent |
| 07/08/2009 | EP2077110A1 Glutamine-containing composition for increasing blood flow |
| 07/08/2009 | EP2077109A1 Amide compound, salt thereof, and biofilm remover using them |
| 07/08/2009 | EP2077108A1 Use of an NMDA receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity |
| 07/08/2009 | EP2077106A1 W/o/w emulsion composition |
| 07/08/2009 | EP2076525A2 Colchicine neoglycosides and methods for their synthesis and use |
| 07/08/2009 | EP2076519A2 Novel dithiolopyrrolones and their therapeutical applications |
| 07/08/2009 | EP2076517A1 Spiro benzazepines as vasopressin antagonists |
| 07/08/2009 | EP2076516A2 Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| 07/08/2009 | EP2076515A1 Thiophene pyrazolopyrimidine compounds |
| 07/08/2009 | EP2076514A1 Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| 07/08/2009 | EP2076512A1 Fused thiazole derivatives as kinase inhibitors |
| 07/08/2009 | EP2076511A1 Novel heteroaryl carboxamides |
| 07/08/2009 | EP2076510A2 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof, and formulations thereof, for the treatment of thrombosis and trombosis related conditions |
| 07/08/2009 | EP2076509A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 07/08/2009 | EP2076508A2 Biaryl ether urea compounds |
| 07/08/2009 | EP2076507A2 Imatinib base, and imatinib mesylate and processes for preparation thereof |
| 07/08/2009 | EP2076506A2 Heterocyclic-substituted piperidines as orl-1 ligands |
| 07/08/2009 | EP2076503A2 C-phenyl glycitol compound for the treatment of diabetes |
| 07/08/2009 | EP2076502A2 Substituted carboxamides as group i metabotropic receptor antagonists |
| 07/08/2009 | EP2076501A2 Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| 07/08/2009 | EP2076499A2 Pyrazine-2-carboxamide derivatives as cb2 receptor modulators |
| 07/08/2009 | EP2076497A1 Aminomethyl-4-imidazoles |
| 07/08/2009 | EP2076496A1 Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors |
| 07/08/2009 | EP2076495A1 Quinoline derivatives with 5-ht-binding properties |
| 07/08/2009 | EP2076494A1 Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds |
| 07/08/2009 | EP2076492A2 Non-nucleoside reverse transcriptase inhibitors |
| 07/08/2009 | EP2076491A1 New benzamide derivatives as bradykinin antagonists |
| 07/08/2009 | EP2076490A1 Cathepsin b inhibitors |
| 07/08/2009 | EP2076489A1 Arylsulfonamidyl tetralin derivatives and uses thereof |
| 07/08/2009 | EP2076487A1 Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives |
| 07/08/2009 | EP2076289A2 Methods for treating cancer resistant to erbb therapeutics |
| 07/08/2009 | EP2076288A2 Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| 07/08/2009 | EP2076282A1 Novel antagonists of the toll-like receptor 4 |
| 07/08/2009 | EP2076273A2 Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin |
| 07/08/2009 | EP2076272A2 Generating an immune response by inducing cd40 and pattern recognition receptors |
| 07/08/2009 | EP2076271A1 Inhibition of cholera toxins by galatooligosaccharides (gos) |
| 07/08/2009 | EP2076270A2 Small molecule intervention for obesity |
| 07/08/2009 | EP2076268A1 Purine derivatives for the treatment of cystic diseases |
| 07/08/2009 | EP2076267A2 Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure |
| 07/08/2009 | EP2076266A2 Method of treating inflammatory diseases using tyroskine kinase inhibitors |
| 07/08/2009 | EP2076265A2 Ketoconazole enantiomer in humans |
| 07/08/2009 | EP2076264A2 Compounds and methods for treatment of hcv |
| 07/08/2009 | EP2076263A2 Discontinuous methods of treating cancer |
| 07/08/2009 | EP2076262A1 Ih channel inhibitors for the promotion of wakefulness |
| 07/08/2009 | EP2076261A2 Muscarinic receptor antagonists |
| 07/08/2009 | EP2076260A1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| 07/08/2009 | EP2076259A2 Methods of treating ovarian cancer |
| 07/08/2009 | EP2076258A2 Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
| 07/08/2009 | EP2076257A2 Polymeric conjugates containing positively-charged moieties |
| 07/08/2009 | EP2076255A2 Use of hypothermia inducing drugs |
| 07/08/2009 | EP2076254A2 Combination with bis(thiohydrazide amides) for treating cancer |
| 07/08/2009 | EP2076253A2 Use of chlorine guanabenz derivatives for treating prion-based diseases |
| 07/08/2009 | EP2076252A2 Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| 07/08/2009 | EP2076251A2 Non-mucoadhesive film dosage forms |